Proteomics for Chronic Disorder of Consciousness

iTRAQ-Based Proteomics Reveals Potential Biomarkers for Chronic Disorder of Consciousness

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03611166

Enrollment

200

Registered

2018-08-02

Start date

2015-11-01

Completion date

2020-01-15

Last updated

2018-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disorder of Consciousness

Keywords

proteomics, plasma, chronic disorder of consciousness

Brief summary

Following severe traumatic brain injury, patients may remain unconscious for many years. It is the first proteomic analysis comparing differentially expressed proteins between patients with chronic disorder of consciousness and controls so far. The investigators generated accurate lists of proteomes and identified differences at different disease time courses. The obtained results provide new insight into understanding the molecular mechanisms underlying the chronic disorder of consciousness.

Detailed description

Background: Patients who awake from severely traumatic brain injury (sTBI) may remain unconscious for many years. Although behavioral assessment and functional imaging are currently used as diagnostic tools, the molecular basis underlying chronic condition has yet to be explored. Objective:To explore the molecular basis and identify novel biomarkers for the diagnosis and prognosis of patients with chronic disorder of consciousness. Method: Plasma samples were obtained from patients with chronic disorder of consciousness, and healthy volunteers. A coupled isobaric tag for relative and absolute quantitation (iTRAQ)-based proteomics approach was used to screen differentially expressed proteins (DEPs) between patients and controls. Potential molecular mechanisms were further discussed through bioinformatics analyses. Candidate proteins were validated by enzyme-linked immunosorbent assay (ELISA).

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

14 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

1. Patients ages 14 to 65 years old; 2. Patients had a history of sTBI; 3. Patients had awakened from a coma (indicating preserved sleep-wake cycles), including vegetative state and minimally consciousness state; 4. Patients stay unconscious for more than 1 month.

Exclusion criteria

1. Patients with acute infectious diseases or liver dysfunction; 2. Patients with serious diseases such as cardiac or pulmonary problems.

Design outcomes

Primary

Measure	Time frame	Description
Protein profiling	Three months	A coupled isobaric tag for relative and absolute quantitation (iTRAQ)-based proteomics approach was used to screen differentially expressed proteins (DEPs) between patients and controls.

Secondary

Measure	Time frame	Description
Glasgow Outcome Scale (GOS)	In one year	A GOS value of \<3 was considered as a bad recovery, while a GOS value of ≥3 was considered as a good recovery.
Coma Recovery Scale-Revised(CRS-R)	30 minutes before blood collection	Coma Recovery Scale-Revised (CRS-R) score was used to quantify the severity, which consists of 23 hierarchically arranged items that comprise six subscales addressing auditory, visual, motor, oromotor/verbal, communication, and arousal processes. The lowest item on each subscale represents reflexive activity, whereas the highest items represent cognitively mediated behaviors.

Countries

China

Contacts

Primary ContactWangxiao Bao, PHD

baowangxiao@zju.edu.cn(86)15057137653

Backup ContactFangping He, PHD

hefangping@126.com(86)13819114225

Outcome results